Jasper Therapeutics, Inc.
JSPR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001788028
No open-market purchases or sales by Jasper Therapeutics, Inc. insiders were filed in the last 90 days; 45 institutions reported holding it in 13F filings for Q2 2026, worth $5.05M in total; no superinvestor holds it.
Other share classesJSPRW
Q3 2023 vs. Q2 2023
How the institutions holding Jasper Therapeutics, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 46 | 41 | −5 |
| Shares | 88.1M | 91.5M | +3.46M (+3.9%) |
| Value | $120.0M | $63.7M | −$56.3M (−46.9%) |
New holders (7)
Institutions that held Jasper Therapeutics, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Saturn V Capital Management LLC | 1,387,015 | $970.9K | 0.41% |
| Scoggin Management LP | 508,045 | $355.6K | 0.48% |
| Cowen and Company, LLC | 200,393 | $140.3K | 0.01% |
| Two Sigma Investments, LP | 66,093 | $46.3K | 0.00% |
| Summit Trail Advisors, LLC | 65,000 | $45.5K | 0.00% |
| Lazard Asset Management LLC | 11,140 | $7.00K | 0.00% |
| FMR LLC | 100 | $70 | 0.00% |
Sold out (12)
Institutions that held Jasper Therapeutics, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Silverarc Capital Management, LLC | 500,000 | $685.0K |
| Jefferies Financial Group Inc. | 489,884 | $671.1K |
| Affinity Asset Advisors, LLC | 476,948 | $653.4K |
| Legal & General Group Plc | 80,000 | $109.6K |
| HRT Financial LP | 41,263 | $56.0K |
| One68 Global Capital, LLC | 20,000 | $27.4K |
| XTX Topco Ltd | 11,286 | $15.5K |
| Virtu Financial LLC | 10,940 | $15.0K |
| Tower Research Capital LLC (TRC) | 9,397 | $12.9K |
| Simplex Trading, LLC | 924 | $1.00K |
| Barclays PLC | 249 | $341 |
| Royal Bank of Canada | 260 | $0 |